165 related articles for article (PubMed ID: 37672055)
1. Discrimination between human epidermal growth factor receptor 2 (HER2)-low-expressing and HER2-overexpressing breast cancers: a comparative study of four MRI diffusion models.
Mao C; Hu L; Jiang W; Qiu Y; Yang Z; Liu Y; Wang M; Wang D; Su Y; Lin J; Yan X; Cai Z; Zhang X; Shen J
Eur Radiol; 2024 Apr; 34(4):2546-2559. PubMed ID: 37672055
[TBL] [Abstract][Full Text] [Related]
2. Discrimination between HER2-overexpressing, -low-expressing, and -zero-expressing statuses in breast cancer using multiparametric MRI-based radiomics.
Zheng S; Yang Z; Du G; Zhang Y; Jiang C; Xu T; Li B; Wang D; Qiu Y; Lin D; Zhang X; Shen J
Eur Radiol; 2024 Feb; ():. PubMed ID: 38363315
[TBL] [Abstract][Full Text] [Related]
3. On a fractional order calculus model in diffusion weighted breast imaging to differentiate between malignant and benign breast lesions detected on X-ray screening mammography.
Bickelhaupt S; Steudle F; Paech D; Mlynarska A; Kuder TA; Lederer W; Daniel H; Freitag M; Delorme S; Schlemmer HP; Laun FB
PLoS One; 2017; 12(4):e0176077. PubMed ID: 28453516
[TBL] [Abstract][Full Text] [Related]
4. Comparison of continuous-time random walk and fractional order calculus models in characterizing breast lesions using histogram analysis.
Tang C; Li F; He L; Hu Q; Qin Y; Yan X; Ai T
Magn Reson Imaging; 2024 May; 108():47-58. PubMed ID: 38307375
[TBL] [Abstract][Full Text] [Related]
5. Assessment of Prognostic Factors and Molecular Subtypes of Breast Cancer With a Continuous-Time Random-Walk MR Diffusion Model: Using Whole Tumor Histogram Analysis.
Qin Y; Tang C; Hu Q; Yi J; Yin T; Ai T
J Magn Reson Imaging; 2023 Jul; 58(1):93-105. PubMed ID: 36251468
[TBL] [Abstract][Full Text] [Related]
6. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
[TBL] [Abstract][Full Text] [Related]
7. Magnetic resonance imaging features in triple-negative breast cancer: comparison with luminal and HER2-overexpressing tumors.
Costantini M; Belli P; Distefano D; Bufi E; Matteo MD; Rinaldi P; Giuliani M; Petrone G; Magno S; Bonomo L
Clin Breast Cancer; 2012 Oct; 12(5):331-9. PubMed ID: 23040001
[TBL] [Abstract][Full Text] [Related]
8. Potential Antihuman Epidermal Growth Factor Receptor 2 Target Therapy Beneficiaries: The Role of MRI-Based Radiomics in Distinguishing Human Epidermal Growth Factor Receptor 2-Low Status of Breast Cancer.
Bian X; Du S; Yue Z; Gao S; Zhao R; Huang G; Guo L; Peng C; Zhang L
J Magn Reson Imaging; 2023 Nov; 58(5):1603-1614. PubMed ID: 36763035
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of breast cancer malignancy, prognostic factors and molecular subtypes using a continuous-time random-walk MR diffusion model.
Chang H; Wang D; Li Y; Xiang S; Yang YX; Kong P; Fang C; Ming L; Wang X; Zhang C; Jia W; Yan Q; Liu X; Zeng Q
Eur J Radiol; 2023 Sep; 166():111003. PubMed ID: 37506477
[TBL] [Abstract][Full Text] [Related]
10. Diffusion-weighted MRI of estrogen receptor-positive, HER2-negative, node-negative breast cancer: association between intratumoral heterogeneity and recurrence risk.
Kim JY; Kim JJ; Hwangbo L; Lee JW; Lee NK; Nam KJ; Choo KS; Kang T; Park H; Son Y; Grimm R
Eur Radiol; 2020 Jan; 30(1):66-76. PubMed ID: 31385051
[TBL] [Abstract][Full Text] [Related]
11. In ER-Positive, HER2-Negative Breast Cancers, HER2 mRNA Levels Correlate Better with Clinicopathologic Features and Oncotype DX Recurrence Score than HER2 Immunohistochemistry.
Tyburski H; Karakas C; Finkelman BS; Turner BM; Zhang H; Hicks DG
Lab Invest; 2024 Mar; 104(3):100309. PubMed ID: 38135156
[TBL] [Abstract][Full Text] [Related]
12. Quantitative Parameters of Diffusion Spectrum Imaging: HER2 Status Prediction in Patients With Breast Cancer.
Mao C; Jiang W; Huang J; Wang M; Yan X; Yang Z; Wang D; Zhang X; Shen J
Front Oncol; 2022; 12():817070. PubMed ID: 35186753
[TBL] [Abstract][Full Text] [Related]
13. Triple-negative invasive breast cancer on dynamic contrast-enhanced and diffusion-weighted MR imaging: comparison with other breast cancer subtypes.
Youk JH; Son EJ; Chung J; Kim JA; Kim EK
Eur Radiol; 2012 Aug; 22(8):1724-34. PubMed ID: 22527371
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
[TBL] [Abstract][Full Text] [Related]
15. HER2-Low Breast Cancer: Incidence, Clinicopathologic Features, and Survival Outcomes From Real-World Data of a Large Nationwide Cohort.
Baez-Navarro X; van Bockstal MR; Andrinopoulou ER; van Deurzen CHM
Mod Pathol; 2023 Apr; 36(4):100087. PubMed ID: 36788086
[TBL] [Abstract][Full Text] [Related]
16. Staging liver fibrosis with various diffusion-weighted magnetic resonance imaging models.
Jiang YL; Li J; Zhang PF; Fan FX; Zou J; Yang P; Wang PF; Wang SY; Zhang J
World J Gastroenterol; 2024 Mar; 30(9):1164-1176. PubMed ID: 38577177
[TBL] [Abstract][Full Text] [Related]
17. The Association between ER, PR, HER2, and ER-/PR+ Expression and Lung Cancer Subsequent in Breast Cancer Patients: A Retrospective Cohort Study Based on SEER Database.
Shao HY; Hao BT; Gao FX
Breast J; 2023; 2023():7028189. PubMed ID: 38021219
[TBL] [Abstract][Full Text] [Related]
18. Development and Validation of MRI Radiomics Models to Differentiate HER2-Zero, -Low, and -Positive Breast Cancer.
Peng Y; Zhang X; Qiu Y; Li B; Yang Z; Huang J; Lin J; Zheng C; Hu L; Shen J
AJR Am J Roentgenol; 2024 Apr; 222(4):e2330603. PubMed ID: 38265001
[No Abstract] [Full Text] [Related]
19. The role of diffusion weighted imaging as supplement to dynamic contrast enhanced breast MRI: Can it help predict malignancy, histologic grade and recurrence?
Roknsharifi S; Fishman MDC; Agarwal MD; Brook A; Kharbanda V; Dialani V
Acad Radiol; 2019 Jul; 26(7):923-929. PubMed ID: 30293819
[TBL] [Abstract][Full Text] [Related]
20. Differences in subtype distribution between screen-detected and symptomatic invasive breast cancer and their impact on survival.
Kobayashi N; Hikichi M; Ushimado K; Sugioka A; Kiriyama Y; Kuroda M; Utsumi T
Clin Transl Oncol; 2017 Oct; 19(10):1232-1240. PubMed ID: 28409323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
